THE AGE OF DISEASE MODIFICATION IN ALZHEIMER'S DISEASE

A Grand Rounds Series on the Implementation of **Amyloid-Targeting Therapy (ATT)** into Clinical Practice

IN THIS FREE VIRTUAL GRAND ROUNDS SESSION, YOU WILL:

- Learn to identify and manage patients interested in amyloid targeting therapy hear directly from experts who are using these therapies in their practices today
- Submit your own questions or cases to have them integrated into the educational content

 Be part of the conversation with real-time discussion, polling, and Q&A

Earn CME credits

EXCLUSIVE SESSION AVAILABLE FOR YOUR CENTER

CURRICULUM LEARNING OBJECTIVES

- Best practices to identify and counsel patients eligible for ATTs
- Safety, efficacy, and logistical requirements of approved and emerging ATTs
- Identification and management of amyloid-related imaging abnormalities (ARIA)

For questions, please email EfficientCME at contact@efficientcme.com.

Bring the experts right to your door



Andrew E. Budson, MD VA Boston Healthcare System

With collective clinical perspectives of **ADDITIONAL EXPERTS** in Alzheimer's disease, including...



James R.
Bateman, MD, MPH
Wake Forest University
School of Medicine



Gayatri Devi, MD, MS, FAAN
Zucker School of Medicine at
Hofstra/Northwell



David A. Wolk, MD
University of Pennsylvania



The Age of Disease Modification in Alzheimer's Disease Pierre N. Tariot, MD
Banner Alzheimer's Institute
University of Arizona
College of Medicine

This activity has been approved for AMA PRA Category 1 Credit™ and is supported through an educational grant from **Lilly**.



